Information about Attana’s presentation at Stora Aktiedagen streamed live on December 2[nd] 09:00-09:30

27 November 2020 - 17:49

Attana will participate at Stora Aktiedagen where CEO Teodor Aastrup will give a 20-minute company presentation followed by a 10-minute Q&A session. Both will be live streamed on December 2nd from 09:00 to 09:30.

The presentation will focus on where Attana stands today, where the company is heading and the plan for getting there. This includes a presentation of the exciting projects planned for 2021, enabled by the upcoming rights issue.

Tentative schedule:

  1. Attana in short
    – Attana’s product and service offering
  2. Recent milestones
    – Important milestones during 2020
  3. Upcoming rights issue
    – Details regarding the upcoming rights issue
  4. Action plan 2021
    – Projects planned for 2021, and where they will take Attana going forward

Follow the presentation here.

For more information, please contact:

Teodor Aastrup, CEO Attana AB
tel: + 46 8 674 57 00

The Board of directors for Attana consider that the information in this press release is not likely to have a significant effect on the share price but is of general interest for the shareholders and hence should be communicated.

About Attana

Attana was founded in 2002 with the vision of in vitro characterization of molecular interactions mimicking in vivo conditions. Since then, Attana has developed proprietary label free biosensors for biochemical, crude, sera, and cell-based assays and the Attana Virus Analytics (AVA) platform, a proprietary in vitro diagnostics (IVD) tool. Attana products and research services are used by Big Pharma, biotech companies and academic institutions within the life sciences. To learn more about our latest services and products, please visit or contact

Provided by: Cision
NGM Nordic SME (Sweden)
Attana AB
Attana conducts research and development of pharmaceuticals. The company specialises in vitro characterization of molecular interactions, which is used for analysis in the development of new pharmaceuticals. The company's patented solutions are mainly used in the study of different binding properties and macrostructures in cells, proteins, viruses, and bacteria. Operations are found mainly within...
Learn more about company

Related news

We use cookies to make your experience using IPOhub better. By using our site you agree to our use of cookies. Learn More

Create Your FREE Account to stay Up To Date